Milestone Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
Milestone Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
MONTREAL and CHARLOTTE, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an upcoming data presentation on etripamil at the annual meeting of the European Society of Cardiology, ESC Congress 2024 in London, United Kingdom on August 30, 2024. Professor John Camm will present patient reported outcomes data from the NODE-303 Phase 3 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) in a moderated poster presentation. The poster presentation will be available following the embargo at: .
2024年8月26日，蒙特利爾和北卡羅來納州夏洛特——里程碑製藥公司（納斯達克代碼：MIST）是一家專注於開發和商業化創新心血管藥物的生物製藥公司，今天宣佈將在歐洲心臟學會年度會議ESC 2024在英國倫敦進行關於Etripamil的數據發佈。 約翰·卡姆教授將在一份主持海報報告中介紹來自NODE-303期3臨床試驗的Etripamil對陣發性早搏性心動過速（PSVT）的患者自報結果數據。 海報報告將於禁令結束後在以下網站上提供：。
"We look forward to Professor Camm's upcoming presentation at the ESC Congress 2024 on this important topic of PSVT and the self-administration of investigational etripamil nasal spray in a medically unsupervised setting," said David Bharucha, MD, PhD, FACC, Chief Medical Officer, Milestone Pharmaceuticals. "These patient-reported outcomes data, that will be presented, provide insights about patient experience, satisfaction, and disease management."
"我們期待卡姆教授在ESC 2024年會議上就PSVt和在醫療無監督環境中應用研究性Etripamil鼻噴劑進行自我管理的相關主題進行的報告。" 里程碑製藥公司首席醫學官David Bharucha博士（MD，PhD，FACC）表示。 "這些即將在報告中提出的患者自報結果數據提供了有關患者體驗，滿意度和疾病管理的見解。"
ESC Presentation Details:
ESC報告詳細信息：
Moderated Poster Presentation Title:
Quality of Life Measures with Etripamil Self-Administration for Acute Episodes of Paroxysmal Supraventricular Tachycardia in a Medically Unsupervised Setting: Patient-Reported Outcomes from NODE-303
主持海報展示標題：
陣發性早搏性心動過速急性發作時Etripamil自我管理的生活質量測量：來自NODE-303的患者自報結果
Presenter:
John Camm, MD, Professor of Clinical Cardiology, St. George's University of London, United Kingdom
地點： McCormick Place South A館
John Camm，醫學博士，倫敦聖喬治大學臨床心臟病學教授，英國
Date and time:
Friday, August 30, 2024, 13:00 – 13:50 BST
日期和時間：
2024年8月30日（星期五）BST時間13:00 – 13:50
About Milestone Pharmaceuticals
關於Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company's focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Milestone Pharmaceuticals Inc.(納斯達克: MIST) 是一家生物醫藥公司，致力於開發和商業化創新的心血管解決方案，以改善那些患有複雜且影響生活的心臟疾病的人們的生活。 公司專注於了解未滿足的患者需求並改善患者體驗，這使我們發展出了提供患者積極參與自我管理護理的新治療方法。 Milestone的主要研究產品是etripamil，一種新型的鈣通道阻滯劑鼻噴霧劑，正在研究中供患者無需醫療監督自行使用，以治療與PSVt和AFib-RVR相關的症狀性陣發性發作。
Contact:
Kim Fox, Vice President, Communications,
kfox@milestonepharma.com
聯繫方式：
金·福克斯，通信副總裁,
kfox@milestonepharma.com
Investor Relations
Chris Calabrese,
ccalabrese@lifesciadvisors.com
投資者關係
克里斯卡拉布萊斯,
ccalabrese@lifesciadvisors.com
Kevin Gardner,
kgardner@lifesciadvisors.com
凱文加德納,
kgardner@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
